New findings in the treatment of panic disorder.
Research conducted during the past decade has resulted in a range of options for treating panic disorder. Favorable responses to tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and high-potency benzodiazepines have been reported. When costs and benefits are taken into account, the selective serotonin uptake inhibitors currently seem to be the treatment of choice. Studies with serotonin agonists and antagonists are as of yet disappointing. The introduction of cholecystokinin antagonists has opened up intriguing new areas of research. This paper reviews those findings and developments.
Department of Biological Psychiatry, Academic Hospital Utrecht, The Netherlands.
H G
HG
Westenberg
J A
JA
Den Boer
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D016584:Panic Disorder / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D001569:Benzodiazepines; D008996:Monoamine Oxidase Inhibitors; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors